Published in Hospital Law Weekly, March 8th, 2007
Study 1: New research, "Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome," is the subject of a report. "The extent of residual carcinoma in resected esophageal cancer specimens after preoperative chemoradiation is a predictor of survival according to 3 groups: P0 (0% residual carcinoma), P1 (1% to 50% residual carcinoma), and P2 (>50% residual carcinoma). However, the interobserver variation and reliability of this classification has...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.